二陈汤合三子养亲汤治疗慢性阻塞性肺疾病痰浊阻肺的Meta分析

Meta Analysis of Erchentanghe Sanziyangqin Decoction in the Treatment of Chronic Obstructive Pulmonary Disease with Phlegm Turbidity and Pulmonary Obstruction

目的:系统评价二陈汤合三子养亲汤治疗慢性阻塞性肺疾病痰浊阻肺的临床疗效以及临床安全性。方法:使用电子计算机搜索CNKI(中国知识资源总库)、Wanfang(万方)、PubMed数据库及CQVIP(维普),文献筛选从建库至2022-03-20中二陈汤合三子养亲汤治疗慢性阻塞性肺疾病痰浊阻肺的RCTs-临床随机对照试验,其中文献筛选和数据提取由2名研究人员独立完成。使用Cochrane系统评价手册对所选的文章进行偏倚风险质量评价,利用Revman5.3软件进行荟萃分析。结果:最后选择14篇临床随机对照试验文献,包含1376名患者,结果显示二陈汤合三子养亲汤治疗慢性阻塞性肺疾病痰浊阻肺的临床效果显著:总体有效率OR=3.46[2.51,4.78],P<0.00001;中医证候积分MD=-0.75[-0.87,-0.64],P<0.00001;肺功能MD=1.29[0.94,1.65],P<0.00001;WBCMD=-1.60[-0.25,-0.69],P=0.0005;CRP OR=-4.03[-4.67,-3.39],P<0.00001;PO2MD=4.67[1.97,7.38],P=0.0007;PCO_(2)MD=-3.74[-8.30,-0.82],P=0.11;CAT积分MD=-8.22[-16.97,-0.53],P=0.07,不良反应少。结论:二陈汤合三子养亲汤治疗慢性阻塞性肺疾病痰浊阻肺临床疗效确切,但是所筛选的文献整体质量水平欠佳,有偏倚风险。希望未来能有更多设计严格、多中心、大样本、质量高的临床随机对照试验进行高层次的研究。

Objective:To systematically evaluate the clinical efficacy and safety of Erchentanghe Sanziyangqin decoction in the treatment of chronic obstructive pulmonary disease with phlegm turbidity and pulmonary obstruction.Methods:Decoction in the treatment of chronic obstructive pulmonary disease.Methods:The computer was used to search CNKI,Wanfang,PubMed and CQVIP databases,and the literature was screened from the establishment of the database to March 20,2022.The RCTs-clinical randomized controlled trial of the treatment of chronic obstructive pulmonary disease (COPD) with turbid phlegm and obstructed lung withErchentanghe Sanziyangqin decoction was conq)leted by two researchers independently.The Cochrane system evaluation manual was used to evaluate the biased risk quality of the selected articles,and the Revman 53 software was used for Meta-analysis.Results:At last,14 clinical randomized controlled trials were selected,including 1376 patients.The results showed that the clinical effect of Erchentanghe Sanziyangqin decoction in the treatment of chronic obstructive pulmonary disease with phlegm turbidity and pulmonary obstruction was significant:the overall effective rate OR=3.46[2.51,4.78],P<0.00001;TCM syndrome score MD=-0.75[-0.87,-0.64],P<0.00001;pulmonary function MD=1.29[0.94,1.65],P<0.00001;WBC MD=1.60[-0.25,-0.69],p=0.0005;CRP OR=4.03[467,-3.39];P<0.00001;PO_(2)MDM.67[1.97,738],p=0.0007;PCO_(2)MD=-3.74[-8.30,-0.82],7MM1;CAT score MD=8.22[-16.97,-0.53],P=0.07,fewer adverse reactions.Conclusion:The clinical effect of Erchentanghe Sanziyangqin decoction in the treatment of chronic obstructive pulmonary disease with phlegm turbidity and pulmonary obstruction is accurate,but the overall quality level of the selected literature is poor and there is a risk of bias.It is hoped that there will be more clinical randomized controlled trials with strict design,multi-center,large sample and high quality for high-level research in the future.